Opexa Therapeutics Provides MS Trial Enrollment Update; 70% Of Patients Enrolled

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126 th patient in the Phase IIb “Abili-T” clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive Multiple Sclerosis (SPMS).

“We are pleased with the continued progress we have made in the Abili-T clinical trial and that patient enrollment has increased steadily over the past several months,” commented Neil K. Warma, Opexa’s President and Chief Executive Officer. “With the enrollment of patient number 126 in the trial, we have reached the 70% enrollment target out of a total of 180 patients. We are continuing our efforts to have the trial fully enrolled in early 2014. Furthermore, we are working with a few additional key multiple sclerosis centers and hope to have two more trial sites up and running shortly to support enrollment. This would increase the total number of clinical trial sites to 35 in the U.S. and Canada. We are especially pleased that many of the first sites that began enrolling patients at the trial’s outset continue to recruit patients into the study. This may reflect the interest that the Secondary Progressive MS patients have in participating in the Abili-T trial and the realization that there are limited treatments options currently available on the market for these patients. Additionally, we are proceeding well with our Immune Monitoring program, which is an important component of the Abili-T trial. The value of the Immune Monitoring program may enable us to evaluate a comprehensive panel of key anti-inflammatory and pro-inflammatory biomarkers associated with MS throughout the course of the Abili-T study. The analysis remains blinded during the course of the trial and we expect it to yield very interesting data on the disease profile of MS and on the mechanism of action of Tcelna.”

Opexa management will be meeting investors in San Francisco from January 13 th through the 16 th, 2014. Please send meeting requests to opexa@troutgroup.com.

About Opexa

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna ®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.

About Multiple Sclerosis (MS)

MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.

About Tcelna

Tcelna ® is a potential personalized therapy that is under development to be specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath™, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named “Abili-T,” the trial is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression with or without associated relapses. The trial is expected to enroll 180 patients at approximately 33 leading clinical sites in the U.S. and Canada with each patient receiving two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months. Study investigators will also measure several important secondary outcomes commonly associated with MS, including disease progression as measured by the Expanded Disability Status Scale (EDSS), annualized relapse rate and changes in disability as measured by EDSS and the MS Functional Composite.

Cautionary Statement Relating to Forward-Looking Information for the Purpose of "Safe Harbor" Provisions of the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements." The words "expects," "believes," "anticipates," "estimates," "may," "could," "intends," “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this release which are not strictly historical statements, including, without limitation, statements regarding the patient enrollment for the ongoing Abili-T clinical trial, development of the Company's product candidate, Tcelna (imilecleucel-T), and the Immune Monitoring program constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, but are not limited to, risks associated with: market conditions; our capital position; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of developing a marketable product; our ability to raise additional capital to continue our development programs (including to undertake and complete any ongoing or further clinical studies for Tcelna), including in this regard our ability to satisfy various conditions required to access the financing potentially available under the purchase agreements with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (such as the minimum closing price for our common stock and the requirement for an ongoing trading market for our stock); our ability to raise additional capital through the sale of shares of our common stock under the purchase agreements with Lincoln Park or under our at-the-market (ATM) facility; our ability to maintain compliance with NASDAQ listing standards; the success of our clinical trials (including the Phase IIb trial for Tcelna in secondary progressive MS which, depending upon results, may determine whether Ares Trading SA (“Merck”) elects to exercise its option for an exclusive license to Tcelna for the treatment of MS (the “Option”)); whether Merck exercises its Option and, if so, whether we receive any development or commercialization milestone payments or royalties from Merck pursuant to the Option; our dependence (if Merck exercises its Option) on the resources and abilities of Merck for the further development of Tcelna; the efficacy of Tcelna for any particular indication, such as for relapsing remitting MS or secondary progressive MS; whether the Immune Monitoring program will yield any useful or valuable data on MS and the mechanism of action of Tcelna; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all Food and Drug Administration regulations; our ability to obtain, maintain and protect intellectual property rights (including for Tcelna); the risk of litigation regarding our intellectual property rights or the rights of third parties; the success of third party development and commercialization efforts with respect to products covered by intellectual property rights that we may license or transfer; our limited manufacturing capabilities; our dependence on third-party manufacturers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in our filings with the SEC. These forward-looking statements speak only as of the date made. We assume no obligation or undertaking to update any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures we make in our Annual Reports on Form 10 K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Copyright Business Wire 2010

If you liked this article you might like

Opexa Shares Jump on Merger with Acer Therapeutics

Opexa Shares Jump on Merger with Acer Therapeutics

These 5 Stocks Under $10 Could Explode Higher Soon

These 5 Stocks Under $10 Could Explode Higher Soon

These 5 Stocks Under $10 Are About to Soar Higher

These 5 Stocks Under $10 Are About to Soar Higher

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Trade-Ideas: Opexa Therapeutics (OPXA) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Opexa Therapeutics (OPXA) Is Today's Weak On High Relative Volume Stock